Company news

Syndax Pharmaceuticals, Inc. news in 2025

Syndax Pharmaceuticals, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Revuforj® (revumenib) Named Best New Drug at the Scrip Awards 2025

December 11, 2025

Syndax Highlights Leadership in Menin Inhibition at ASH 2025 with Multiple Revuforj® (revumenib) Presentations Spanning the Acute Leukemia Treatment Continuum

December 7, 2025

Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference

November 30, 2025

Syndax Reports Third Quarter 2025 Financial Results and Provides Business Update

November 2, 2025

Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025

November 2, 2025

Syndax Announces Compelling Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr) Data Accepted for Presentation at ASH 2025

November 2, 2025

Syndax Announces Participation in November Investor Conferences

October 29, 2025

Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025

October 26, 2025

Syndax Announces FDA Approval of Revuforj® (revumenib) in Adult and Pediatric Patients with Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

October 23, 2025

CREATE Medicines Strengthens Executive Team with Appointment of Veteran Biopharma Leader Allan L. Shaw as CFO and CBO

October 8, 2025

Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia

September 18, 2025

Syndax Announces Participation in September Investor Conferences

August 25, 2025

Syndax Reports Second Quarter 2025 Financial Results and Provides Business Update

August 3, 2025

Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025

July 27, 2025

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia

June 23, 2025

Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025

June 11, 2025

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

June 11, 2025

Syndax Announces Participation in June Investor Conferences

May 28, 2025

Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)

May 13, 2025

Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer

May 11, 2025

Syndax Announces Participation in May Investor Conferences

May 7, 2025

Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood

May 6, 2025

Syndax Reports First Quarter 2025 Financial Results and Provides Business Update

May 4, 2025

Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025

April 27, 2025

Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum

April 1, 2025

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 2, 2025

Syndax Announces Participation in March Investor Conferences

February 24, 2025

Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

February 23, 2025

Syndax Announces Participation in February Investor Conferences

January 29, 2025

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

January 14, 2025

Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

January 12, 2025

Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference

January 6, 2025

Calls in 2025

Decks in 2025